Stocktoria
Dianthus Therapeutics, Inc. /DE/ DNTH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-06-21
Chart by TradingView
1/9
Piotroski F — financial health
14.17
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $2.0M | $6.2M | $2.8M | — | — |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$29.7M | -$74.7M |
| Net income | -$162.3M | -$85.0M | -$43.6M | -$28.5M | -$71.1M |
| Operating cash flow | -$129.1M | -$78.2M | -$36.9M | -$29.1M | -$59.5M |
| Free cash flow | — | — | — | -$29.4M | -$60.8M |
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M | $189.9M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M | $17.3M |
| Shareholders' equity | $493.4M | $352.5M | $168.9M | -$44.4M | -$17.2M |
| Ratios | |||||
| Operating margin | -8739.3% | -1633.7% | -1704.7% | — | — |
| Net margin | -7973.3% | -1362.8% | -1541.2% | — | — |
| Return on assets | -30.6% | -22.7% | -24.3% | -34.3% | -37.5% |
| Return on equity | -32.9% | -24.1% | -25.8% | 64.2% | 412.4% |
| Current ratio | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 |
| Revenue growth | -67.3% | 120.6% | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 643,599 | $54.0M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 14.17 (safe)
- Working capital / assets 0.713
- Retained earnings / assets -0.634
- EBIT / assets -0.335
- Equity / liabilities 13.15
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001690585 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.